Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Name: Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
License: Public Domain

Fudan University

ClinicalTrials.gov · Datasets · License: Public Domain

her2-positive gastric cancer, immunotherapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 160342
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.